Nov 16, 2020
Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society
Sep 30, 2020
Harbour BioMed Announces Dosing of First Patients in Two Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia
Sep 21, 2020
Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors
Sep 01, 2020
Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020
Aug 31, 2020
Harbour BioMed Will Present Its New Platform HBICE (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit
Aug 24, 2020
Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases
Aug 21, 2020
Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020
Aug 19, 2020
Harbour BioMed, Utrecht University, Erasmus Medical Center, Viroclinics-DDL and Kiadis Pharma Announce Collaboration to Develop Monoclonal Antibody, Natural Killer Cell Combination Approach to Treating COVID-19
Jun 11, 2020
Harbour BioMed Appoints Dr. Jon Wigginton to its Scientific Advisory Board
Jun 05, 2020
AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
Apr 21, 2020
Harbour BioMed Announces First Patient Dosing of Phase 1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder